Biomarkers in Routine Heart Failure Clinical Care

Heart failure is a clinical condition with complex pathophysiology that involves many different processes. Diagnosis is often difficult in patients presenting for the first time with breathlessness. Many biomarkers have been identified that are elevated in heart failure and their role in assessing p...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadar, Sunil K, Shaikh, Mohammad Mujtaba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2019
Materias:
Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396063/
https://www.ncbi.nlm.nih.gov/pubmed/30847246
http://dx.doi.org/10.15420/cfr.2018.27.2
_version_ 1783399196241428480
author Nadar, Sunil K
Shaikh, Mohammad Mujtaba
author_facet Nadar, Sunil K
Shaikh, Mohammad Mujtaba
author_sort Nadar, Sunil K
collection PubMed
description Heart failure is a clinical condition with complex pathophysiology that involves many different processes. Diagnosis is often difficult in patients presenting for the first time with breathlessness. Many biomarkers have been identified that are elevated in heart failure and their role in assessing prognosis has also been investigated. However, at present the natriuretic peptides appear to be the gold standard biomarker against which the other biomarkers are compared. In this review we will examine the evidence behind the other biomarkers for use in heart failure patients and the current guidelines for their use.
format Online
Article
Text
id pubmed-6396063
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Radcliffe Cardiology
record_format MEDLINE/PubMed
spelling pubmed-63960632019-03-07 Biomarkers in Routine Heart Failure Clinical Care Nadar, Sunil K Shaikh, Mohammad Mujtaba Card Fail Rev Biomarkers Heart failure is a clinical condition with complex pathophysiology that involves many different processes. Diagnosis is often difficult in patients presenting for the first time with breathlessness. Many biomarkers have been identified that are elevated in heart failure and their role in assessing prognosis has also been investigated. However, at present the natriuretic peptides appear to be the gold standard biomarker against which the other biomarkers are compared. In this review we will examine the evidence behind the other biomarkers for use in heart failure patients and the current guidelines for their use. Radcliffe Cardiology 2019-02 /pmc/articles/PMC6396063/ /pubmed/30847246 http://dx.doi.org/10.15420/cfr.2018.27.2 Text en Copyright © 2019, Radcliffe Cardiology https://creativecommons.org/licenses/by-nc/4.0/legalcode This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.
spellingShingle Biomarkers
Nadar, Sunil K
Shaikh, Mohammad Mujtaba
Biomarkers in Routine Heart Failure Clinical Care
title Biomarkers in Routine Heart Failure Clinical Care
title_full Biomarkers in Routine Heart Failure Clinical Care
title_fullStr Biomarkers in Routine Heart Failure Clinical Care
title_full_unstemmed Biomarkers in Routine Heart Failure Clinical Care
title_short Biomarkers in Routine Heart Failure Clinical Care
title_sort biomarkers in routine heart failure clinical care
topic Biomarkers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396063/
https://www.ncbi.nlm.nih.gov/pubmed/30847246
http://dx.doi.org/10.15420/cfr.2018.27.2
work_keys_str_mv AT nadarsunilk biomarkersinroutineheartfailureclinicalcare
AT shaikhmohammadmujtaba biomarkersinroutineheartfailureclinicalcare

Ejemplares similares